Equilium

Equilium is a clinical-stage biotechnology company focused on developing novel therapies for severe autoimmune and inflammatory disorders with high unmet medical need. The company's lead program, itolizumab, is a first-in-class monoclonal antibody targeting the CD6-ALCAM pathway, currently in Phase 3 clinical development for acute graft-versus-host disease. Equilium is also advancing a pipeline of multi-cytokine inhibitors, including EQ101 and EQ302, which target synergistic cytokine pathways to treat conditions like alopecia areata and atopic dermatitis. By modulating the activity of effector T cells, Equilium aims to provide transformative treatments for patients suffering from complex immuno-inflammatory diseases.